attained.ai

12/01/2024

Jesteśmy już w styczniu, a to idealny moment na inwestycję w rozwój osobisty i zawodowy 🌟.

Zapraszam serdecznie na szkolenia, które poprowadzę pod koniec lutego. Szkolenia są organizowane przez Centralny Ośrodek Badań, Innowacji i Kształcenia Naczelna Izba Lekarska.

Zapisy na sezon zimowo-wiosenny są otwarte. Nie przegapcie okazji do zdobycia cennej wiedzy!

Szczegóły i rejestracja pod tych linkach 👇

https://nil.org.pl/dla-lekarzy/kursy-i-szkolenia/994-deep-learning-w-diagnostyce-nowa-era

https://nil.org.pl/dla-lekarzy/kursy-i-szkolenia/980-data-science-w-medycynie-innowacje-w-rozwoju

🇬🇧
January is here, and it's the perfect time to invest in your personal and professional development 🌟.

I'm excited to announce that I will be conducting training sessions at the end of February. These are organized by the Central Research, Innovation, and Education Center of the Supreme Medical Chamber.

Registration for the winter-spring season is now open. Don't miss this opportunity to gain valuable knowledge!

For more details and to register, visit these links👇

https://nil.org.pl/dla-lekarzy/kursy-i-szkolenia/994-deep-learning-w-diagnostyce-nowa-era

https://nil.org.pl/dla-lekarzy/kursy-i-szkolenia/980-data-science-w-medycynie-innowacje-w-rozwoju

08/11/2023

My takeaways for Health Tech from last week's inaugural AI Safety Summit in the UK brought together international minds to shape the future of AI governance.

The dialogues resonated deeply with healthcare technology, and I'd like to share some critical takeaways:

1. Consensus Reached – But It's Still Early Days

Health tech must now navigate the Bletchley Declaration, promising safe, human-centric AI. Consider Google Gemini's implications for personalized medicine: How do we harness such power responsibly?

2. Sharing is Caring

The summit underlined collaboration for AI safety. Transparent AI development is key, just as sharing clinical trial data improves outcomes. Can health tech firms openly share safety protocols without compromising competitive advantage?

3. Open Source AI Crowd Disagrees

Open-source advocates argue that accessibility promotes innovation and safety in AI. As health tech relies increasingly on open-source AI for developments like drug discovery, how might over-regulation stifle this vital resource?

4. China Plays Ball

China's participation signals a commitment to global AI safety standards, an encouraging move for health tech companies looking to operate internationally. Will this lead to a harmonized approach to AI in global health markets?

5. More AI Safety Summits to Come

Future summits are set to solidify these conversations. The real question for health tech is whether these discussions will translate into actionable standards that foster both innovation and patient safety.

The Summit's dialogues bring us to the precipice of a new era in health tech, one where global cooperation and safety are paramount. What remains to be seen is how these high-level agreements will manifest in the nuanced, high-stakes world of healthcare technology.

https://www.linkedin.com/posts/dominikstosik_my-takeaways-for-health-tech-from-last-weeks-activity-7127916235828174848-V6LL?utm_source=share&utm_medium=member_ios

04/09/2023

Is Health Tech the Missing Piece in Solving the Long Covid Puzzle?

As a medical doctor and founder of a health tech startup, a recent study on long Covid had me contemplating. I remember people like i.e. Prof. Bohdan Wasilewski were talking about this already years ago:

• How pivotal is technology in shaping our evolving understanding of this multi-organ menace?

• Can AI algorithms improve early detection of organ-specific long Covid symptoms? I believe they can.

• What if long Covid isn't just a prolonged state as we are currently assuming but a transformational shift in the patient's health dynamics? What if its not just merely a 'sequel' to an acute episode, should we position it as a standalone, multi-organ health issue?

• If the lungs (mostly) recover but other organs might not, is our treatment protocol or diagnostic protocol flawed?

• Should we leverage neural networks to forecast the progression of long Covid in different demographics?

• If mitochondrial dysfunction in the lungs can have a domino effect on the heart, how should this change cardiological screenings?

My statistics professor used to say, "You don't argue with data." So, since the data urges us to look beyond the lungs, isn't AI the tool we need to embrace?

I believe that as we navigate the complex world of Long Covid, our usual medical approaches are falling short. The need now isn't just to adjust, but to completely rethink how we diagnose and treat this condition. Can health tech be the spark that drives this big change, going beyond what humans alone can see or calculate?

and ... is this actually a question or our next big task?

Over 65 million worldwide are affected by long Covid, which can linger for up to years.

19/02/2023

It was a pleasure to be part of discussions at the GovTech Summit in The Hague about the future of and with Maddy Phipps-Taylor Stein Olav Skrøvseth Dr Anas Nader André Rogaczewski
State-of-the-art AI/ML technology and use of human voice and heart sound as a biomarker will revolutionize healthcare!
Thanks to the amazing team of PUBLIC everyone from The GovTech Summit Adam from PUBLIC and the friendly photographer I forgot the name out of nervousness and Accelerate Estonia. Very special thanks from Mats and myself to Piret Hirv !
You can re-watch the video here

Healthcare systems across the world are struggling after over two years of operating in crisis mode during the COVID-19 pandemic - and whilst we saw innovati...